Athira Pharma, Inc. (NASDAQ:LONA) Receives Consensus Rating of “Hold” from Brokerages

Athira Pharma, Inc. (NASDAQ:LONA) has been assigned a consensus rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $15.00.

A number of equities research analysts have recently issued reports on LONA shares. Piper Sandler started coverage on shares of Athira Pharma in a research report on Wednesday. They set an “overweight” rating and a $20.00 price objective for the company. Cantor Fitzgerald started coverage on shares of Athira Pharma in a research report on Thursday, February 26th. They set an “overweight” rating for the company. Zacks Research raised shares of Athira Pharma to a “hold” rating in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Monday, May 11th. Finally, Mizuho raised shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Thursday, February 19th.

Athira Pharma Stock Performance

Shares of LONA opened at $9.67 on Wednesday. The stock has a market cap of $90.80 million, a price-to-earnings ratio of -1.86 and a beta of 1.98. The company’s fifty day moving average is $9.72. Athira Pharma has a 1-year low of $2.64 and a 1-year high of $14.21.

Athira Pharma (NASDAQ:LONA) last announced its earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share for the quarter. Research analysts expect that Athira Pharma will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mark James Litton sold 5,156 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total value of $27,687.72. Following the completion of the transaction, the chief executive officer owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This represents a 8.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 9,110 shares of company stock valued at $48,921. Corporate insiders own 25.73% of the company’s stock.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.